Volume 35, Issue 4 pp. 456-464

Effects of Rosuvastatin on Serum Asymmetric Dimethylarginine Levels and Atrial Structural Remodeling in Atrial Fibrillation Dogs

JINGJIE LI M.D.,

JINGJIE LI M.D.

Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China

Search for more papers by this author

WEI XIA M.D.,

WEI XIA M.D.

Department of Cardiology, Qingdao Municipal Hospital, Qingdao, China

Search for more papers by this author

WEI FENG M.S.,

WEI FENG M.S.

Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China

Search for more papers by this author

XIUFEN QU Ph.D.,

Corresponding Author

XIUFEN QU Ph.D.

Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China

Address for reprints: Xiufen Qu, Ph.D., Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, China. Fax: +86-451-53670428. e-mail: [email protected]Search for more papers by this author

JINGJIE LI M.D.,

JINGJIE LI M.D.

Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China

Search for more papers by this author

WEI XIA M.D.,

WEI XIA M.D.

Department of Cardiology, Qingdao Municipal Hospital, Qingdao, China

Search for more papers by this author

WEI FENG M.S.,

WEI FENG M.S.

Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China

Search for more papers by this author

XIUFEN QU Ph.D.,

Corresponding Author

XIUFEN QU Ph.D.

Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China

First published: 13 January 2012

https://doi.org/10.1111/j.1540-8159.2011.03308.x

Citations: 9

Authors Jingjie Li and Wei Xia contributed equally to the manuscript.

Conflict of interest: None.

Share a link

Email
Wechat
Bluesky

Abstract

Background: Circulating asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is increased in atrial fibrillation (AF). The purpose of this study was to investigate the effects of rosuvastatin on serum ADMA levels and atrial structural remodeling in AF dogs induced by chronic rapid atrial pacing.

Methods: Twenty dogs were randomly divided into the sham-operated (n = 6), control (n = 7), or rosuvastatin (n = 7) groups. Sustained AF was induced by rapid pacing of the right atrium at 400 beats per minute for 6 weeks. Rosuvastatin was administered orally (1 mg/kg d) for 3 days before rapid pacing and was continued for 6 weeks. Transthoracic and transesophageal echocardiography were performed to detect left atrial structure and function. Serum levels of nitric oxide and ADMA were measured. Interstitial fibrosis and cardiomyocyte apoptosis in the atria were also identified.

Results: After 6 weeks, compared with the control group, dramatic smaller left atrium and left atrial appendage volumes and higher atrial contractile function were observed in the rosuvastatin group. Serum nitric oxide concentration was increased, whereas ADMA was decreased in the rosuvastatin group compared with the control group. The percentages of interstitial fibrosis and atrial apoptosis in the control group were significantly higher than those in the sham-operated group, and rosuvastatin attenuated these changes induced by atrial rapid pacing.

Conclusion: A short course of rosuvastatin treatment decreased apoptosis and prevented atrial structural remodeling in association with a decrease in ADMA levels in AF dogs. PACE 2012; 35:456–464)

References

1 Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, Bosker HA, et al. Continuous vs. episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: A randomized trial. JAMA 2008; 300: 1784–1792.
10.1001/jama.300.15.1784
CAS PubMed Web of Science® Google Scholar
2 Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230–246.
10.1016/S0008-6363(02)00258-4
CAS PubMed Web of Science® Google Scholar
3 Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160–170.
10.1016/j.ijcard.2007.07.137
PubMed Web of Science® Google Scholar
4 Cengel A, Sahinarslan A, Biberoğlu G, Hasanoğlu A, Tavil Y, Tulmaç M, Ozdemir M. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol 2008; 63: 33–37.
10.2143/AC.63.1.2025329
PubMed Web of Science® Google Scholar
5 Xia W, Qu X, Yu Y, Zhang X, Feng W, Song Y. Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol 2008; 31: 1036–1040.
10.1111/j.1540-8159.2008.01131.x
CAS PubMed Web of Science® Google Scholar
6 Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 2009; 32: 1562–1566.
10.1111/j.1540-8159.2009.02554.x
PubMed Web of Science® Google Scholar
7 Chang CM, Wu TJ, Zhou S, Doshi RN, Lee MH, Ohara T, Fishbein MC, et al. Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. Circulation 2001; 103: 22–25.
10.1161/01.CIR.103.1.22
CAS PubMed Web of Science® Google Scholar
8 Li Y, Li WM, Gong YT, Li BX, Liu W, Han W, Dong D, et al. The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs. Basic Res Cardiol 2007; 102: 245–256.
10.1007/s00395-007-0641-8
CAS PubMed Web of Science® Google Scholar
9 Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400–405.
10.1111/j.1540-8167.2008.01182.x
CAS PubMed Web of Science® Google Scholar
10 Marín F, Pascual DA, Roldán V, Arribas JM, Ahumada M, Tornel PL, Oliver C, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55–60.
10.1016/j.amjcard.2005.07.124
CAS PubMed Web of Science® Google Scholar
11 Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, Nattel S. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007; 74: 75–84.
10.1016/j.cardiores.2007.01.002
CAS PubMed Web of Science® Google Scholar
12 Porter KE, Turner NA, O'Regan DJ, Balmforth AJ, Ball SG. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61: 745–755.
10.1016/j.cardiores.2003.11.032
CAS PubMed Web of Science® Google Scholar
13 Tziakas DN, Chalikias GK, Stakos DA, Papanas N, Chatzikyriakou SV, Mitrousi K, Maltezos E, et al. Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation. Am J Cardiol 2008; 101: 199–202.
10.1016/j.amjcard.2007.07.063
CAS PubMed Web of Science® Google Scholar
14 Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, Tseng CD, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: Implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008; 117: 344–355.
10.1161/CIRCULATIONAHA.107.695346
CAS PubMed Web of Science® Google Scholar
15 Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, Yang GS, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008; 29: 1578–1590.
10.1093/eurheartj/ehn167
PubMed Web of Science® Google Scholar
16 Vilahur G, Casaní L, Peña E, Duran X, Juan-Babot O, Badimon L. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 2009; 206: 95–101.
10.1016/j.atherosclerosis.2009.02.009
CAS PubMed Web of Science® Google Scholar
17 Zhao H, Liao Y, Minamino T, Asano Y, Asakura M, Kim J, Asanuma H, et al. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 2008; 31: 1977–1987.
10.1291/hypres.31.1977
CAS PubMed Web of Science® Google Scholar
18 Chen MS, Xu FP, Wang YZ, Zhang GP, Yi Q, Zhang HQ, Luo JD. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004; 37: 889–896.
10.1016/j.yjmcc.2004.06.019
CAS PubMed Web of Science® Google Scholar
19 Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T, Komuro I. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35: 953–960.
10.1016/S0022-2828(03)00180-9
CAS PubMed Web of Science® Google Scholar
20 Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004; 110: 412–418.
10.1161/01.CIR.0000136088.18960.E6
CAS PubMed Web of Science® Google Scholar
21 Bergmann MW, Rechner C, Freund C, Baurand A, El Jamali A, Dietz R. Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: Role for glycogen synthase kinase 3beta and transcription factor beta-catenin. J Mol Cell Cardiol 2004; 37: 681–690.
10.1016/j.yjmcc.2004.05.025
CAS PubMed Web of Science® Google Scholar
22 Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–1135.
10.1161/01.CIR.97.12.1129
CAS PubMed Web of Science® Google Scholar
23 Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004–1010.
10.1038/79510
CAS PubMed Web of Science® Google Scholar
24 Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Böhm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102: 3104–3110.
10.1161/01.CIR.102.25.3104
CAS PubMed Web of Science® Google Scholar
25 Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation 2002; 106: 2854–2858.
10.1161/01.CIR.0000039327.11661.16
CAS PubMed Web of Science® Google Scholar
26 Hu YF, Chen YC, Cheng CC, Higa S, Chen YJ, Chen SA. Fluvastatin reduces pulmonary vein spontaneous activity through nitric oxide pathway. J Cardiovasc Electrophysiol 2009; 20: 200–206.
10.1111/j.1540-8167.2008.01281.x
CAS PubMed Web of Science® Google Scholar
27 Ivashchenko CY, Bradley BT, Ao Z, Leiper J, Vallance P, Johns DG. Regulation of the ADMA-DDAH system in endothelial cells: A novel mechanism for the sterol response element binding proteins, SREBP1c and −2. Am J Physiol Heart Circ Physiol 2010; 298: H251–H258.
10.1152/ajpheart.00195.2009
CAS PubMed Web of Science® Google Scholar
28 Jiang DJ, Jia SJ, Dai Z, Li YJ. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J Mol Cell Cardiol 2006; 40: 529–539.
10.1016/j.yjmcc.2006.01.021
CAS PubMed Web of Science® Google Scholar
29 Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682–1688.
10.1161/01.ATV.0000136656.26019.6e
CAS PubMed Web of Science® Google Scholar
30 Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM. The renin-angiotensin-system: A therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol 2006; 29: 1006–1012.
10.1111/j.1540-8159.2006.00477.x
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume35, Issue4

April 2012

Pages 456-464

Effects of Rosuvastatin on Serum Asymmetric Dimethylarginine Levels and Atrial Structural Remodeling in Atrial Fibrillation Dogs

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effects of Rosuvastatin on Serum Asymmetric Dimethylarginine Levels and Atrial Structural Remodeling in Atrial Fibrillation Dogs

Abstract

References

Citing Literature

References

Related

Information